文摘

Mesalazine其肾毒性与阿斯匹林、非那西汀结构相似,当静脉注射高剂量的老鼠。肾毒性的病例数在病人服用口服mesalazine近日报道。敏感的一组患者的肾功能指标保持在长期来看,延迟释放mesalazine sulphasalazine和类似的小组研究了。六十二名患者(32人,28 - 82岁)与静止结肠炎进行了研究。三十四一直保持延迟释放mesalazine 1.6(0.8 - -2.4)克/天为2.9(0.5 - -6.9)岁和28 sulphasalazine 2 g /天(2 - 3)。组与年龄、性别、疾病持续时间,和疾病的程度。肾功能评估:尿液显微镜;肌酐清除率;两个标记的尿排泄的肾小球毒性、白蛋白和转铁蛋白;和两个标记的尿排泄管毒性,N-acetyl-beta-D-glucosaminidase(唠叨)和α1-microglobulin。 There were no significant differences in renal function between the two treatment groups. Furthermore, no correlations were found between measures of renal function and either cumulative mesalazine dose or mesalazine treatment duration. In this study, long term maintenance treatment with delayed release mesalazine was no more nephrotoxic than continued treatment with sulphasalazine.